U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1073
Full Text
Open PDFAbstract
Available in full text
Date
October 28, 2016
Authors
Publisher
American Association for Cancer Research (AACR)